Form D · Biotechnology
Savanna Biotherapeutics, Inc.
Aliso Viejo, CA · CIK 0001873404
Offering snapshot reported Jun 30, 2025 · SEC filing
- Reported sold
- $13M Offering amount: $60M
- Investors reported
- 30 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 12, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 30, 2025 | Initial | $12,999,997 | No comparison | 30 | SEC filing |
| Nov 18, 2022 | Initial | $24,304,480 | No comparison | 54 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-550314
Source: Form D, filed Jun 30, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey W. Bird | Director |
| Kim Kamdar | Director |
| Keith Loebner | Director |
| Michael L. Speiser | Director |
| Robert Spitale | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O University Lab Partners, Curie Hall 1 University Drive
Aliso Viejo, CA, 92656
Aliso Viejo, CA, 92656